There are currently 1201 ongoing clinical trials involving Squamous Cell Carcinoma
Of the 1201 trials,461 trials are in Phase II
Furthermore, 239 trials are in Phase III
The global pharmaceutical industry is steadily developing new drugs for Squamous Cell Carcinoma, an oncology condition. The largest number of ongoing clinical trials for Squamous Cell Carcinoma is conducted in the Asia-Pacific region. North America and Europe are among some of the other prominent regions engaged in Squamous Cell Carcinoma-related drug trials.
National Cancer Institute US: The leading ongoing Squamous Cell Carcinoma related clinical trial sponsor
National Cancer Institute US is the top sponsor for Squamous Cell Carcinoma-related ongoing clinical trials.
Sun Yat-sen University, University of Texas MD Anderson Cancer Center, Merck & Co Inc, Shanghai Jiao Tong University School of Medicine, and The General Hospital of the People's Liberation Army are among other notable clinical trial sponsors involved in Squamous Cell Carcinoma. A clinical trial sponsor can be a Company, Government, Individual, or Institution.
Marketed Drugs involving Squamous Cell Carcinoma
Pembrolizumab (Keytruda), Human papillomavirus types L1 proteins 6, 11, 16, and 18 (Gardasil / Silgard), and Cemiplimab (Libtayo) are key marketed drugs involving Squamous Cell Carcinoma.
Pembrolizumab (Keytruda) is an antineoplastic immunomodulating agent. It functions via Programmed Cell Death Protein 1 Antagonist mechanism of action. Keytruda is formulated as lyophilized powder for solution, solution concentrate for intravenous route of administration. Keytruda is indicated for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation-positive, a BRAF inhibitor. Keytruda as monotherapy is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults. Pembrolizumab was first approved in 2014 and is marketed globally including in the US, the UK, Australia, France, Germany, China, and Japan by Merck Sharp & Dohme Corp.
Human papillomavirus types L1 proteins 6, 11, 16, and 18 (Gardasil / Silgard) is an adjuvant non-infectious recombinant quadrivalent vaccine that acts as immunizing preparation against humans papillomavirus. It is formulated as suspension for injection administered by intramuscular route. It is a vaccine for use from the age of 9 years for the prevention of premalignant genital lesions (cervical, vulvar and vaginal) and cervical cancer causally related to certain oncogenic Human Papillomavirus (HPV) types and for the treatment of genital warts (condyloma acuminata) causally related to specific HPV types. Gardasil indicated in girls and women 9 through 26 years of age for the prevention of the following diseases caused by Human Papillomavirus (HPV) types included in the vaccine: cervical, vulvar, vaginal and anal cancer caused by HPV types 16 and 18, genital warts (condyloma acuminata) caused by HPV types 6 and 11 and the following precancerous or dysplastic lesions caused by HPV types 6, 11, 16, and 18: cervical intraepithelial neoplasia (CIN) grade 2/3 and Cervical adenocarcinoma in situ (AIS), cervical intraepithelial neoplasia (CIN) grade 1, vulvar intraepithelial neoplasia (VIN) grade 2 and grade 3, vginal intraepithelial neoplasia (VaIN) grade 2 and grade 3, anal intraepithelial neoplasia (AIN) grades 1, 2, and 3. Human papillomavirus types L1 proteins 6, 11, 16, and 18 were first approved in 2006 and is marketed globally including in the US, the UK, Australia, France, Germany, and Japan by Merck Sharp & Dohme Corp.
United States of America
China
Switzerland
United States of America
United States of America
United States of America
United States of America
Germany
France
Switzerland
Don’t wait - discover a universe of connected data & insights with your next search. Browse over 28M data points across 22 industries.
Access more premium companies when you subscribe to Explorer
Contact the team or request a demo to find out how our data can drive your business forward